Home Newsletters Immunology of Infectious Disease News SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral...

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

By
Justin.choi
-
0
SyneuRx™ International announced it has completed enrollment for its Phase II clinical trial evaluating the efficacy and safety of SNB01 (‘Pentarlandir’), a novel COVID-19 oral antiviral candidate.
[SyneuRx™ International]
6445212 BBBBBBBB items 1 apa 0 default asc 1 174024 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
Press Release

RELATED ARTICLES

Exit mobile version